Blosozumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | SOST |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
1132758-87-2  |
| ChemSpider | none |
| KEGG |
D10094 |
| Chemical and physical data | |
| Formula | C6462H9852N1684O2030S46 |
| Molar mass | 144.63 kg/mol |
 (what is this?) (verify) | |
Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.[1]
Blosozumab was developed by Eli Lilly and Company.
References
- ↑ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).
This article is issued from Wikipedia - version of the 9/25/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.